All News
Today is June 02, 2024. All times in Eastern Daylight Time.
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
06/02/2024 - 02:32 PM
BUSINESS WIRE
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
06/02/2024 - 12:30 PM
BUSINESS WIRE
Stronger Than Ever: Adani Portfolio Delivers Record Performance
06/02/2024 - 12:09 PM
BUSINESS WIRE
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
06/02/2024 - 10:56 AM
BUSINESS WIRE
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
06/02/2024 - 10:01 AM
BUSINESS WIRE
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
06/02/2024 - 09:30 AM
BUSINESS WIRE
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
06/02/2024 - 09:00 AM
BUSINESS WIRE
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
06/02/2024 - 08:30 AM
BUSINESS WIRE
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
06/02/2024 - 08:30 AM
BUSINESS WIRE
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
06/02/2024 - 08:05 AM
BUSINESS WIRE
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
06/02/2024 - 08:00 AM
BUSINESS WIRE
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
06/02/2024 - 08:00 AM
BUSINESS WIRE
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
06/02/2024 - 08:00 AM
BUSINESS WIRE
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the United States and Europe
06/02/2024 - 08:00 AM
BUSINESS WIRE
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
06/02/2024 - 08:00 AM
BUSINESS WIRE
Accutar Biotechnology在2024年ASCO年會上公布了在ER陽性/HER2陰性乳癌病患中展開AC699單一療法第一期試驗的資料
06/02/2024 - 07:40 AM
BUSINESS WIRE
June Joy at Juicy Stakes Casino
06/02/2024 - 07:00 AM
BUSINESS WIRE
Bihar collabora con Bidgely per ridurre i furti di energia e le perdite di ricavi tramite l'analisi dei dati alimentata dall'IA
06/01/2024 - 03:42 PM
BUSINESS WIRE
Accutar Biotechnology、ASCO 2024にてER +/ HER2-乳がん患者におけるAC699単剤療法の第1相試験データを発表
06/01/2024 - 02:42 PM
BUSINESS WIRE
Accutar Biotechnology在2024年ASCO年会上公布了在ER+/HER2-乳腺癌患者中开展AC699单一疗法一期试验的数据
06/01/2024 - 02:30 PM
BUSINESS WIRE
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
06/01/2024 - 02:25 PM
BUSINESS WIRE
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
06/01/2024 - 02:20 PM
BUSINESS WIRE
ADSK Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Autodesk, Inc. - Contact Kessler Topaz Meltzer & Check, LLP
06/01/2024 - 10:01 AM
BUSINESS WIRE
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
06/01/2024 - 10:00 AM
BUSINESS WIRE
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
06/01/2024 - 10:00 AM
BUSINESS WIRE
1
2
3
4
5
6
7
8
9
10
11
...
600
Next »
Site Navigation
Home
Home
Submit a Press Release
Services
News
All News
News with Multimedia
News by Industry
News by Subject
News by Language
Tradeshows & Events
Education
Overview
Blog
Distribution & Media
Media & Journalist Tools
Sample Press Release
Find Your News Online
Disclosure Resources
About Us
Overview
Become a Member
Contact Us
Careers
Business Wire Newsroom
Business Wire Events
Search
Advanced News Search
Advanced News Search
Log In
Sign Up